
    
      The purpose of the study is to demonstrate the efficacy and safety of inclisiran sodium 300mg
      to support the indication for LDL-C reduction of inclisiran in Asian patients with
      atherosclerotic cardiovascular disease (ASCVD) or ASCVD-high risk patients with elevated
      LDL-C as an adjunct to diet and maximally tolerated dose statins with or without additional
      lipid-lowering therapy.

      A core part (2-week screening period and a 12-month double-blinded treatment period), and an
      extension part (until reasonable access to the IMP post product launch provided for the
      participants)
    
  